Michael Richman
CIK 1366265 · President & CEO · last filed 2026-02-03
Michael Richman is a President & CEO who has filed 57 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for NXTC, was dated Feb 3, 2026.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
6
57
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NXTC | President & CEO | — | $2.08 | — | $0 | 8 | 2026-02-03 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Director | — | $13.60 | — | $0 | 24 | 2023-06-23 |
| GENVEC INC (GNVC) Delisted | Director | — | — | — | $0 | 3 | 2016-10-24 |
| Acer Therapeutics Inc. (OPXAW) Delisted | Director | 25,884 | — | — | $0 | 17 | 2016-10-04 |
| Cougar Biotechnology, Inc. (CGRB) Delisted | Director | 0 | — | — | $0 | 2 | 2009-07-07 |
| Acer Therapeutics Inc. (OPXA) Delisted | Director | — | — | — | $0 | 1 | 2007-06-19 |
Recent Filings
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-03 | NXTC | Grant (A) | — | $0 | EDGAR |
| 2025-02-03 | NXTC | Grant (A) | — | $0 | EDGAR |
| 2024-04-02 | NXTC | Grant (A) | — | $0 | EDGAR |
| 2024-02-01 | NXTC | Grant (A) | — | $0 | EDGAR |
| 2023-06-23 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-03-01 | NXTC | Grant (A) | — | $0 | EDGAR |
| 2022-06-24 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-02-02 | NXTC | Grant (A) | — | $0 | EDGAR |
| 2021-06-29 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-03-16 | NXTC | Grant (A) | — | $0 | EDGAR |